Loading...
Back to narrative

Update shared on08 Oct 2025

Fair value Increased 1.77%
AnalystConsensusTarget's Fair Value
US$100.75
10.1% undervalued intrinsic discount
08 Oct
US$90.54
Loading
1Y
-13.1%
7D
-3.9%

Narrative Update on Entegris: Analyst Price Target Revision

Analysts have slightly increased their price target for Entegris from $99.00 to $100.75, reflecting modest adjustments in key financial assumptions and updated forecasts.

What's in the News

  • Entegris issued earnings guidance for the third quarter ending September 27, 2025, and projects sales between $780 million and $820 million (Key Developments).
  • The company anticipates GAAP net income in the range of $65 million to $76 million for the same period (Key Developments).
  • Diluted earnings per common share are expected to be between $0.43 and $0.50 (Key Developments).

Valuation Changes

  • Fair Value increased modestly from $99.00 to $100.75.
  • Discount Rate decreased slightly from 11.35% to 11.32%.
  • Revenue Growth edged down from 6.40% to 6.31%.
  • Net Profit Margin declined fractionally from 12.95% to 12.69%.
  • Future P/E has risen from 41.60x to 43.27x.

Disclaimer

AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.